Uni-Bio Science Group

Uni-Bio Science Group Gross Margin

The Gross Margin of Uni-Bio Science Group (690.HK) as of Oct 22, 2026 is 83.38 %. In the previous year, Gross Margin was 81.04 % — a change of 2.89% (higher).

Gross Margin

83.38 %

YoY

2.89%

Last updated:

Gross Margin of Uni-Bio Science Group is 2024 83.38 % . Gross Margin of Uni-Bio Science Group was 2023 81.04 % . It decreases by 2.89% higher compared to the previous year.

For Uni-Bio Science Group, the gross margin of 83.4% is down versus 86.7% a few years ago.

The Uni-Bio Science Group Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2017
85.40 HKD
Jan 1, 2018
86.95 HKD
Jan 1, 2019
86.66 HKD
Jan 1, 2020
86.74 HKD
Jan 1, 2021
78.38 HKD
Jan 1, 2022
76.06 HKD
Jan 1, 2023
81.04 HKD
Jan 1, 2024
83.38 HKD
The Uni-Bio Science Group Gross Margin history
YEARGross MarginYoY
83.38 %+2.89%
81.04 %+6.55%
76.06 %-2.97%
78.38 %-9.64%
86.74 %+0.09%
86.66 %-0.32%
86.95 %+1.81%
85.40 %+1.00%
84.56 %+1.51%
83.29 %-0.27%
83.52 %+10,337.25%
0.80 %+0.54%
0.80 %+18.45%
0.67 %+8.18%
0.62 %+19.31%
0.52 %-15.78%
0.62 %-0.00%
0.62 %+13.78%
0.54 %+214.37%
0.17 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Uni-Bio Science Group Stock analysis

What does Uni-Bio Science Group do? Uni-Bio Science Group Ltd. generates revenue through four segments: in-house chemical pharmaceutical products like Pinapu, in-house biological pharmaceutical products such as GeneTime and GeneSoft, in-house biological pipeline products including Uni-E4 and Uni-PTH, and third-party pharmaceutical products. The company manufactures and sells its own chemical and biological products while also distributing third-party pharmaceuticals. Its primary customers are healthcare providers and pharmaceutical distributors purchasing these branded products. The firm's revenue streams are directly tied to the production and distribution of these specific branded pharmaceuticals across its operational segments. The in-house chemical pharmaceutical segment focuses on products like Pinapu, which is sold to medical institutions and pharmacies. The biological pharmaceutical segment markets GeneTime and GeneSoft for specialized treatments, targeting hospitals and clinics. The biological pipeline segment develops Uni-E4 and Uni-PTH for future commercialization, while third-party pharmaceutical sales involve distributing external brands without direct manufacturing. These segments collectively drive the company's revenue through product sales and distribution agreements. Uni-Bio Science Group's business model relies on both direct manufacturing of its branded pharmaceuticals and third-party product distribution. The company's revenue comes from the sale of Pinapu, GeneTime, GeneSoft, Uni-E4, and Uni-PTH as well as third-party pharmaceuticals. Healthcare institutions and pharmaceutical distributors are the key buyers of these products across all segments, with the in-house products forming the core of the company's revenue generation strategy. Uni-Bio Science Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Uni-Bio Science Group stock

Gross Margin of Uni-Bio Science Group is 83.38 % in 2024.

Gross Margin of Uni-Bio Science Group changed from 81.04 % to 83.38 %, representing a 2.89% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Uni-Bio Science Group since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Uni-Bio Science Group with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Uni-Bio Science Group

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Uni-Bio Science Group